Trial · NCT07443956
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
NCT07443956, Not applicable, Recruiting, NHS Greater Glasgow and Clyde
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis. Trials, record NCT07443956. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07443956
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
- NCT number
- NCT07443956
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 45 participants, estimated
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Conditions
- Psoriatic Arthritis (PsA), Obesity & Overweight
- Interventions
- Ixekizumab, Tirzepatide
- First posted
- 2026-03-02
- Last updated
- 2026-05-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss | 12 weeks | Percentage change in weight (in kg) from baseline will be correlated with changes in molecular markers in tissues (synovium, skin and adipose). This is an experimental medicine (and not efficacy) study that will utilise a range of advanced spatial and other tissue omics to measure molecular markers in these tissues at baseline and 12 weeks. It is not possible or appropriate to specify a single biomarker or measure for this. |
| Secondary | Correlation of changes in molecular signatures in the peripheral blood with weight loss. | 12 weeks | Percentage change in weight (in kg) from baseline will be correlated with changes in molecular markers in peripheral blood. This is an experimental medicine (and not efficacy) study that will utilise a range of advanced techniques to measure molecular markers in blood at baseline and 12 weeks. It is not possible or appropriate to specify a single biomarker or measure for this. |
| Secondary | Comparison of molecular changes in biopsies (skin, synovial and adipose) and in the peripheral blood with weight loss versus those with immunomodulation by IL-17A inhibition. | 12 weeks | Comparison of molecular changes in biopsies (skin, synovial and adipose) and in the peripheral blood with % change in weight (in kg) from baseline will be compared between the three treatment arms. A range of advanced analyses will be used to evaluate the correlation of molecular (immune) changes in tissues (synovium, skin and adipose) and peripheral blood with weight loss alone, compared with changes seen with immunomodulation alone or immunomodulation in combination with weight loss. It is not possible or appropriate to specify a single biomarker. |
| Other | Correlation of changes in molecular signatures in the peripheral blood with weight loss. | Weeks 4, 24, 36 and 52. | Percentage change in weight (in kg) from baseline will be correlated with changes in molecular markers in peripheral blood. This is an experimental medicine (and not efficacy) study that will utilise a range of advanced techniques to measure molecular markers in blood. It is not possible or appropriate to specify a single biomarker or measure for this. |
| Other | Correlation of changes in weight with PsA disease activity measures. | Weeks 4, 12, 24, 36 and 52. | Percentage change in weight (in kg) from baseline will be correlated with validated PsA disease activity measures (66/68 joint counts, MDA, DAPSA, CRP, PASI, PROs). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07443956
GET https://conductscience.org/api/trials/v1/NCT07443956/registered